IDI, Inc. COGT 深 滬
已收盤 08-29 16:00:00 美东时间
12.08
0.000
0.00%
華盛通- 最 高12.21
- 今 開12.08
- 成交量 106.08万股
- 最 低 11.8804
- 昨 收 12.08
- 總市值 16.91亿
- 52周最高 12.97
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 3.72
- 委 比 1.51%
- 總股本 1.40亿
- 歷史最高 27.80
- 量 比 1.10
- 振 幅 2.73%
- 歷史最低 3.67
- 每 手 1
- 風險率 2.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $20
Guggenheim analyst Charles Zhou maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $17 to $20.
08-25 20:21
CarParts.com Reports Second Quarter 2025 Results
TORRANCE, Calif., Aug. 12, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ: PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle rep...
08-13 04:01
WOW! REPORTS SECOND QUARTER 2025 RESULTS
Greenfield markets now pass 91.1 thousand homes with a penetration rate at 16.0% ENGLEWOOD, Colo., Aug. 11, 2025 /PRNewswire/ -- WideOpenWest, Inc. ("WOW!" or the "Company") (NYSE: WOW), one...
08-12 04:54
AVALON HOLDINGS CORPORATION ANNOUNCES SECOND QUARTER RESULTS
WARREN, Ohio, Aug. 8, 2025 /PRNewswire/ -- Avalon Holdings Corporation (NYSE Amex: AWX) today announced financial results for the second quarter of 2025. Net operating revenues in the second...
08-09 05:05
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $30
JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $29 to $30.
08-08 03:10
Century Casinos, Inc. Announces Second Quarter 2025 Results
Company Initiates Strategic Review Process to Enhance Shareholder Value. COLORADO SPRINGS, Colo., Aug. 7, 2025 /PRNewswire/ -- Century Casinos, Inc. (the "Company", "we", "us", or "our") (Na...
08-07 18:00
Analysts’ Top Healthcare Picks: Cogent Biosciences (COGT), Adaptive Biotechnologies (ADPT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-06 18:50
Cogent Biosciences Q2 EPS $(0.53) Beats $(0.58) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.58) by 9.4 percent. This is a 10.17 percent increase over losses of $(0.59) per share from
08-06 05:45
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved ...
08-06 04:05
